Perhexiline
Phase 3Small molecule
Perhexiline is one of 73 small molecule programs targeting Left Ventricular Hypertrophy. It is currently in Phase 3.
3
Indications
8
Total Trials
0
Active Trials
72
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
687 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Perhexiline
UUniversity Hospital Birmingham
Phase 3
Bayer Aspirin
BayerPreclinical
Brethine
SanofiPreclinical
Medrol
PfizerPreclinical
LCZ696
NovartisPreclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Oraverse
LLife Extension Foundation Inc.
Preclinical
Kuvan
BioMarin PharmaceuticalPreclinical
GLP-1
RRigshospitalet, Denmark
Preclinical
Jardiance
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypertrophic Cardiomyopathy3 trials
Heart Failure2 trials
Left Ventricular Hypertrophy1 trial
Surgery1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Perhexiline. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity Hospital Birmingham